CRISPR/Cas-9, Cha-Ching | GenomeWeb

The flow of money to startups trying to leverage CRISPR/Cas-9 technology for clinical purposes apparently is limitless. 

Intellia Therapeutics this week said that it raised $70 million in a Series B funding round that drew some heavyweight investors, including OrbiMed HealthCare Fund Management, Fidelity Management and Research, Janus Capital Management, and others. Founding investors Atlas Venture and Novartis also participated in the round. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.